ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ian W. Flinn, Caron Alyce Jacobson, Loretta J. Nastoupil, Franck Morschhauser, Andrew Davies, Christian Buske, Paolo Corradini, Armando López Guillermo, Ran Reshef, Vinod Parameswaran, Alison Sehgal, Michael Timothy Tees, Christine Lui, Wei Xue, Sara Beygi, Nikolay Grechko, Pisita Bolsue, Alessandro Giovanetti, Christina Ann To, Myrna Nahas
Institutions: Sarah Cannon, Tennessee Oncology, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Université de Lille, Centre Hospitalier Universitaire de Lille, University of Southampton, Universität Ulm, University Hospital Ulm, Fondazione IRCCS Istituto Nazionale dei Tumori, Universitat de Barcelona, Columbia University Irving Medical Center, Avera Health, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Colorado Blood Cancer Institute, Kite (United States)
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379329765